Konstantin Konstantinov - 28 Mar 2023 Form 4 Insider Report for Codiak BioSciences, Inc.

Reporting relationship: Chief Technology Officer
Issuer ticker: N/A
Reported as of: 28 Mar 2023
Net transaction value: -$1,874
SEC form: 4
Accepted by SEC: 30 Mar 2023, 17:13:35 UTC
Prior SEC filing: 26 Jan 2023
Next SEC filing: 22 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Yalonda Howze, Attorney-in-Fact for Konstantin Konstantinov

Key filing fact

Konstantin Konstantinov filed Form 4 for Codiak BioSciences, Inc. on 30 Mar 2023.

Key facts

This page summarizes Konstantin Konstantinov's Form 4 filing for Codiak BioSciences, Inc..
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 30 Mar 2023, 17:13.

Change

Previous filing in this sequence was filed on 26 Jan 2023.
Current net transaction value: -$1,874.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CDAKQ transaction

Common Stock

Sale

Transaction value: $1,487
Shares: -7,432
Change %: -79%
Price: $0.2001^*
Shares after: 1,932
Date: 28 Mar 2023
Ownership: Direct
Footnotes: F1

CDAKQ transaction

Common Stock

Sale

Transaction value: $386
Shares: -1,932
Change %: -100%
Price: $0.2000^*
Shares after: 0
Date: 28 Mar 2023
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Includes an aggregate of 1,932 shares of common stock acquired on June 30, 2022 and December 30, 2022 under the Issuer's Employee Stock Purchase Plan (ESPP).